<div id="readability-page-1"><div id="ctl00_CPI_dvBody"><p>Eli Lilly and Co. (LLY) announced Friday the successful completion of its acquisition of Verve Therapeutics, Inc. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.</p><p>Lilly said the acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment.</p><p>On June 17, Lilly agreed to acquire Verve for up to $13.50 per share or up to around $1.3 billion, including around $1.0 billion in cash. </p><p>For comments and feedback contact: editorial@rttnews.com</p><p>Business News</p></div></div>

VERV

<p>Eli Lilly and Co. has successfully completed its acquisition of Verve Therapeutics, a Boston-based company focused on genetic medicines for cardiovascular disease. The deal, valued at up to $1.3 billion, aims to transform treatment options for patients by providing lifelong cardiovascular risk reduction through a single treatment.</p>

Lilly Completes Acquisition Of Verve Therapeutics